ClinicalTrials.gg
RecruitingNCT07159074Updated Nov 5, 2026

Repurposing Tilmanocept for Cardiac Sarcoidosis

A Phase 2 interventional study of Tc 99m tilmanocept and Tc 99m tilmanocept in Cardiac Sarcoidosis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Duke University · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.

Planned enrollment
37th of 69
15 · median 16
Started
2025
with 3 others
Phase 2
26 of 115
4 open now
Primary completion
2026-12
later than 2 of 24 live
Registered
113th of 115
by date
Lead sponsor
4 of 115
Duke University

Among the 115 studies in Sarcoidosis with a site in United States, this one is the 37th largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2025, is one of 26 in phase 2, reaches primary completion later than 2 of the 24 other live ones, and was the 113th registered.

Sarcoidosis

271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.

Browse Sarcoidosis studies →

Open to participants now

23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Sarcoidosis studies recruiting now, 30 (73%) set no upper age limit and 1 (2%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoidosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if Tc 99m Tilmanocept SPECT/CT imaging can be used to identify cardiac sarcoidosis.

03

Conditions studied

  • Cardiac Sarcoidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1:

  1. The participant has provided written with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.
  2. Women of must have a negative urine pregnancy test at the time of the study.
  3. The participant is at least 18 years of age.
  4. The participant has a histological diagnosis sarcoidosis and meets 2014 HRS, 2014 WASOG, or 2016 JCS criteria for cardiac sarcoidosis.
  5. The participant has had a clinically indicated cardiac PET-CT showing cardiac activity in the past 14 days.
  6. The participant has had a prior cardiac MRI with delayed enhancement in pattern consistent with cardiac sarcoidosis as defined in the AHA Scientific Statement on the Diagnosis and Management of Cardiac Sarcoidosis (2024).

Cohort 2:

  1. The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.
  2. Women of reproductive potential must have a negative urine pregnancy test at the time of the study.
  3. The participant is at least 18 years of age.
  4. Cardiac sarcoidosis has been clinically excluded.
  5. The participant has an arrhythmogenic, non-ischemic cardiomyopathy defined as the presence of a cardiomyopathy with a history of recurrent (more than 1 episode) ventricular tachycardia, atrial arrhythmias, high grade AV block not due to ischemic heart disease

Exclusion criteria

Exclusion Criteria:

  1. The participant is pregnant or lactating.
  2. The participant size or weight is not compatible with imaging per the investigator.
  3. The participant has renal insufficiency as demonstrated by a of \< 30 mL/min.
  4. The participant has hepatic insufficiency as demonstrated by (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the .
  5. The participant has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.
  6. The participant has a known allergy to or has had an adverse reaction to dextran exposure.
  7. The participant has received an product within 30 days prior to the Tc 99m tilmanocept administration (Day 0).
  8. The participant has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Tc 99m Tilmanocept SPECT CT imaging (intravenously)

    Participants with known cardiac sarcoidosis and a cardiac positron emission tomography (PET) imaging study showing active inflammation in the past 14 days or participants with a cardiomyopathy for which sarcoidosis has been excluded will undergo Single Photon Emission Computed Tomography (SPECT-CT) imaging after administration of Tc 99m Tilmanocept intravenously (IV).

    Drug: Tc 99m tilmanocept

  • Experimental
    Tc 99m Tilmanocept SPECT CT imaging (subcutaneously)

    Participants with known cardiac sarcoidosis and a cardiac positron emission tomography (PET) imaging study showing active inflammation in the past 14 days or participants with a cardiomyopathy for which sarcoidosis has been excluded will undergo Single Photon Emission Computed Tomography (SPECT-CT) imaging after administration of Tc 99m Tilmanocept subcutaneously (SC).

    Drug: Tc 99m tilmanocept

Interventions

06

What researchers measure

Primary outcomes

  1. Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with fluorodeoxyglucose (FDG) uptake on cardiac PET-CT. For each imaging modality, a standard 17-segment cardiac model will be used.

    Time frame: At the time of the scan (Baseline)

Secondary outcomes

  1. Correlation between TUVmax from tilmanocept imaging and SUVmax from FDG-PET imaging.

    Time frame: At the time of the scan (Baseline)

  2. Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with hyperenhancement on cardiac MRI. For each imaging modality, a standard 17-segment cardiac model will be used.

    Time frame: At the time of the scan (Baseline)

  3. Correlation of extracardiac sites with tilmanocept uptake and FDG uptake attributed to sarcoidosis.

    Time frame: At the time of the scan (Baseline)

  4. Difference in percentage of segments with tilmanocept uptake in cohort 1 compared to cohort 2

    Time frame: At the time of the scan (Baseline)

  5. Adverse events, identified through clinical laboratory results (hematology, serum chemistry, vital signs).

    Time frame: 1 year

  6. Difference in biodistribution measured by cardiac uptake relative to liver uptake

    Time frame: Baseline

  7. Difference in biodistribution measured by uptake of the upper extremity musculature

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 8, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07159074
Lead sponsor
Duke University
Collaborators
Foundation for Sarcoidosis Research
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 17, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Shaheela Fnu
Contact
ravi.karra@duke.edu
919-681-2723
Ravi Karra, MD
principal investigator · Duke Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Technetium tc-99m tilmanocept

Start the discussion